Update on the impact of type 2 diabetes mellitus on bone metabolism and material properties

Endocrine Connections

Volumn 8, Issue 3, 2019, Pages R55-R70

  Picke, Ann Kristin ^a   Campbell, Graeme ^b   Napoli, Nicola ^c,d   Hofbauer, Lorenz C ^e   Rauner, Martina ^e  

^a UNIVERSITY OF ULM   (Germany)

^b HAMBURG UNIVERSITY OF TECHNOLOGY   (Germany)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^d WASHINGTON UNIVERSITY   (United States)

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Bone; Diabetes

Indexed keywords

ALKALINE PHOSPHATASE; ANTIDIABETIC AGENT; BETA CATENIN; BONE MORPHOGENETIC PROTEIN; C REACTIVE PROTEIN; CARBOXY TERMINAL TELOPEPTIDE; FIBROBLAST GROWTH FACTOR 23; GLUCOSE; HEMOGLOBIN A1C; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROCOLLAGEN C PROTEINASE; SCLEROSTIN; THY 1 MEMBRANE GLYCOPROTEIN; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; VITAMIN D; WNT11 PROTEIN;

ADIPOGENESIS; ANTIOSTEOPOROTIC ACTIVITY; APOPTOSIS RATE; BONE AGE; BONE DENSITY; BONE DEVELOPMENT; BONE DISEASE; BONE FRAGILITY; BONE MARROW; BONE METABOLISM; BONE MICROARCHITECTURE; BONE MINERALIZATION; BONE STRENGTH; BONE TURNOVER; CALORIC INTAKE; CELL DIFFERENTIATION; COMPUTER ASSISTED TOMOGRAPHY; DIABETIC COMPLICATION; DISEASE DURATION; FRACTURE; GENE OVEREXPRESSION; GLYCEMIC CONTROL; HEALTH IMPACT ASSESSMENT; HOMEOSTASIS; HUMAN; INFLAMMATION; INFLAMMATORY INFILTRATE; MACROPHAGE; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OSSIFICATION; OSTEOBLAST; OSTEOCLAST ACTIVITY; OSTEOCYTE; OSTEOLYSIS; PATHOGENESIS; POROSITY; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SEDENTARY LIFESTYLE; SIGNAL TRANSDUCTION; WNT SIGNALING;

EID: 85064184060     PISSN: None     EISSN: 20493614     Source Type: Journal    
DOI: 10.1530/EC-18-0456     Document Type: Review

References (184)

1. American Diabetes Association. Economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care 1998. 21 296-309. (https://doi.org/10.2337/diacare.21.2.296)
2. International Diabetes Federation. IDF Diabetes Atlas, 8th ed Brussels, Belgium: IDF, 2017.
3. Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. American Journal of Epidemiology 2007. 166 495-505. (https://doi.org/10.1093/aje/kwm106)
4. Napoli N, Chandran M, Pierroz DD, Abrahamsen B, Schwartz AV, Ferrari SL. & IOF Bone and Diabetes Working Group. Mechanisms of diabetes mellitus-induced bone fragility. Nature Reviews Endocrinology 2017. 13 208-219. (https://doi.org/10.1038/nrendo.2016.153)
5. Hofbauer LC, Brueck CC, Singh SK, Dobnig H. Osteoporosis in patients with diabetes mellitus. Journal of Bone and Mineral Research 2007. 22 1317-1328. (https://doi.org/10.1359/jbmr.070510)
6. Napoli N, Strotmeyer ES, Ensrud KE, Sellmeyer DE, Bauer DC, Hoffman AR, Dam TTL, Barrett-Connor E, Palermo L, Orwoll ES, et al Fracture risk in diabetic elderly men: the MrOS study. Diabetologia 2014. 57 2057-2065. (https://doi.org/10.1007/s00125-014-3289-6)
7. Napoli N, Schwartz AV, Black DM. & Osteoporotic Fractures in Men (MrOS) Study Research Group. Reply to: indications of increased vertebral fracture risk in patients with type 2 diabetes. Journal of Bone and Mineral Research 2018. 33 183 (https://doi.org/10.1002/jbmr.3322)
8. Napoli N, Jin J, Peters K, Wustrack R, Burch S, Chau A, Cauley J, Ensrud K, Kelly M, Black DM. Are women with thicker cortices in the femoral shaft at higher risk of subtrochanteric/diaphyseal fractures? The study of osteoporotic fractures. Journal of Clinical Endocrinology and Metabolism 2012. 97 2414-2422. (https://doi.org/10.1210/jc.2011-3256)
9. Purnamasari D, Puspitasari MD, Setiyohadi B, Nugroho P, Isbagio H. Low bone turnover in premenopausal women with type 2 diabetes mellitus as an early process of diabetes-associated bone alterations: a cross-sectional study. BMC Endocrine Disorders 2017. 17 72 (https://doi.org/10.1186/s12902-017-0224-0)
10. Krakauer JC, McKenna MJ, Buderer NF, Rao DS, Whitehouse FW, Parfitt AM. Bone loss and bone turnover in diabetes. Diabetes 1995. 44 775-782. (https://doi.org/10.2337/diab.44.7.775)
11. Leite Duarte ME, da Silva RD. Histomorphometric analysis of the bone tissue in patients with non-insulin-dependent diabetes (DMNID). Revista do Hospital das Clinicas 51 7-11.
12. Napoli N, Strollo R, Defeudis G, Leto G, Moretti C, Zampetti S, D’Onofrio L, Campagna G, Palermo A, Greto V, et al Serum sclerostin and bone turnover in latent autoimmune diabetes in adults. Journal of Clinical Endocrinology and Metabolism 2018. 103 1921-1928. (https://doi.org/10.1210/jc.2017-02274)
13. Hygum K, Starup-Linde J, Harsløf T, Vestergaard P, Langdahl BL. Mechanisms in endocrinology: diabetes mellitus, a state of low bone turnover - a systematic review and meta-analysis. European Journal of Endocrinology 2017. 176 R137-R157. (https://doi.org/10.1530/EJE-16-0652)
14. Hamann C, Picke AK, Campbell GM, Balyura M, Rauner M, Bernhardt R, Huber G, Morlock MM, Günther KP, Bornstein SR, et al Effects of parathyroid hormone on bone mass, bone strength, and bone regeneration in male rats with type 2 diabetes mellitus. Endocrinology 2014. 155 1197-1206. (https://doi.org/10.1210/en.2013-1960)
15. Hamann C, Rauner M, Höhna Y, Bernhardt R, Mettelsiefen J, Goettsch C, Günther KP, Stolina M, Han CY, Asuncion FJ, et al Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. Journal of Bone and Mineral Research 2013. 28 627-638. (https://doi.org/10.1002/jbmr.1803)
16. Won HY, Lee JA, Park ZS, Song JS, Kim HY, Jang SM, Yoo SE, Rhee Y, Hwang ES, Bae MA. Prominent bone loss mediated by RANKL and IL-17 produced by CD4+ T cells in TallyHo/JngJ mice. PLoS ONE 2011. 6 e18168 (https://doi.org/10.1371/journal.pone.0018168)
17. Devlin MJ, Vliet M Van, Motyl K, Karim L, Brooks DJ, Louis L, Conlon C, Rosen CJ, Bouxsein ML. Early-onset type 2 diabetes impairs skeletal acquisition in the male TALLYHO/JngJ mouse. Endocrinology 2014. 155 3806-3816. (https://doi.org/10.1210/en.2014-1041)
18. Xu F, Dong Y, Huang X, Li M, Qin L, Ren Y, Guo F, Chen A, Huang S. Decreased osteoclastogenesis, osteoblastogenesis and low bone mass in a mouse model of type 2 diabetes. Molecular Medicine Reports 2014. 10 1935-1941. (https://doi.org/10.3892/mmr.2014.2430)
19. Ma YHV, Schwartz AV, Sigurdsson S, Hue TF, Lang TF, Harris TB, Rosen CJ, Vittinghoff E, Eiriksdottir G, Hauksdottir AM, et al Circulating sclerostin associated with vertebral bone marrow fat in older men but not women. Journal of Clinical Endocrinology and Metabolism 2014. 99 E2584-E2590. (https://doi.org/10.1210/jc.2013-4493)
20. Janghorbani M, Feskanich D, Willett WC, Hu F. Prospective study of diabetes and risk of hip fracture: the Nurses’ Health Study. Diabetes Care 2006. 29 1573-1578. (https://doi.org/10.2337/dbib6-0440)
21. Forsén L, Meyer HE, Midthjell K, Edna TH. Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trøndelag Health Survey. Diabetologia 1999. 42 920-925. (https://doi.org/10.1007/s001250051248)
22. Ahmed LA, Joakimsen RM, Berntsen GK, Fønnebø V, Schirmer H. Diabetes mellitus and the risk of non-vertebral fractures: the Tromsø study. Osteoporosis International 2006. 17 495-500. (https://doi.org/10.1007/s00198-005-0013-x)
23. Patsch JM, Burghardt AJ, Yap SP, Baum T, Schwartz AV, Joseph GB, Link TM. Increased cortical porosity in type 2 diabetic postmenopausal women with fragility fractures. Journal of Bone and Mineral Research 2013. 28 313-324. (https://doi.org/10.1002/jbmr.1763)
24. Pritchard JM, Giangregorio LM, Atkinson SA, Beattie KA, Inglis D, Ioannidis G, Gerstein H, Punthakee Z, Adachi JD, Papaioannou A. Changes in trabecular bone microarchitecture in postmenopausal women with and without type 2 diabetes: a two year longitudinal study. BMC Musculoskeletal Disorders 2013. 14 114 (https://doi.org/10.1186/1471-2474-14-114)
25. Pritchard JM, Giangregorio LM, Atkinson SA, Beattie KA, Inglis D, Ioannidis G, Punthakee Z, Adachi JD, Papaioannou A. Association of larger holes in the trabecular bone at the distal radius in postmenopausal women with type 2 diabetes mellitus compared to controls. Arthritis Care and Research 2012. 64 83-91. (https://doi.org/10.1002/acr.20602)
26. Burghardt AJ, Issever AS, Schwartz AV, Davis KA, Masharani U, Majumdar S, Link TM. High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 2010. 95 5045-5055. (https://doi.org/10.1210/jc.2010-0226)
27. Karim L, Bouxsein ML. Effect of type 2 diabetes-related non-enzymatic glycation on bone biomechanical properties. Bone 2016. 82 21-27. (https://doi.org/10.1016/j.bone.2015.07.028)
28. Farr JN, Drake MT, Amin S, Melton LJ, McCready LK, Khosla S. In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. Journal of Bone and Mineral Research 2014. 29 787-795. (https://doi.org/10.1002/jbmr.2106)
29. Furst JR, Bandeira LC, Fan WW, Agarwal S, Nishiyama KK, McMahon DJ, Dworakowski E, Jiang H, Silverberg SJ, Rubin MR. Advanced glycation endproducts and bone material strength in type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2016. 101 2502-2510. (https://doi.org/10.1210/jc.2016-1437)
30. Nordklint AK, Almdal TP, Vestergaard P, Lundby-Christensen L, Boesgaard TW, Breum L, Gade-Rasmussen B, Sneppen SB, Gluud C, Hemmingsen B, et al The effect of metformin versus placebo in combination with insulin analogues on bone mineral density and trabecular bone score in patients with type 2 diabetes mellitus: a randomized placebo-controlled trial. Osteoporosis International 2018. 29 2517-2526. (https://doi.org/10.1007/s00198-018-4637-z)
31. Leslie WD, Aubry-Rozier B, Lamy O, Hans D. & Manitoba Bone Density Program. TBS (trabecular bone score) and diabetes-related fracture risk. Journal of Clinical Endocrinology and Metabolism 2013. 98 602-609. (https://doi.org/10.1210/jc.2012-3118)
32. Kim JH, Choi HJ, Ku EJ, Kim KM, Kim SW, Cho NH, Shin CS. Trabecular bone score as an indicator for skeletal deterioration in diabetes. Journal of Clinical Endocrinology and Metabolism 2015. 100 475-482. (https://doi.org/10.1210/jc.2014-2047)
33. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006. 114 597-605. (https://doi.org/10.1161/CIRCULATIONAHA.106.621854)
34. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern D. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. Journal of Clinical Investigation 1995. 96 1395-1403. (https://doi.org/10.1172/JCI118175)
35. Howard EW, Benton R, Ahern-Moore J, Tomasek JJ. Cellular contraction of collagen lattices is inhibited by nonenzymatic glycation. Experimental Cell Research 1996. 228 132-137. (https://doi.org/10.1006/excr.1996.0308)
36. Poundarik AA, Wu PC, Evis Z, Sroga GE, Ural A, Rubin M, Vashishth D. A direct role of collagen glycation in bone fracture. Journal of the Mechanical Behavior of Biomedical Materials 2015. 52 120-130. (https://doi.org/10.1016/j.jmbbm.2015.08.012)
37. Garnero P, Borel O, Gineyts E, Duboeuf F, Solberg H, Bouxsein ML, Christiansen C, Delmas PD. Extracellular post-translational modifications of collagen are major determinants of biomechanical properties of fetal bovine cortical bone. Bone 2006. 38 300-309. (https://doi.org/10.1016/j.bone.2005.09.014)
38. Tang SY, Zeenath U, Vashishth D. Effects of non-enzymatic glycation on cancellous bone fragility. Bone 2007. 40 1144-1151. (https://doi.org/10.1016/j.bone.2006.12.056)
39. Saito M, Mori S, Mashiba T, Komatsubara S, Marumo K. Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs. Osteoporosis International 2008. 19 1343-1354. (https://doi.org/10.1007/s00198-008-0585-3)
40. Sanguineti R, Storace D, Monacelli F, Federici A, Odetti P. Pentosidine effects on human osteoblasts in vitro. Annals of the New York Academy of Sciences 2008. 1126 166-172. (https://doi.org/10.1196/annals.1433.044)
41. Ogawa N, Yamaguchi T, Yano S, Yamauchi M, Yamamoto M, Sugimoto T. The combination of high glucose and advanced glycation end-products (AGEs) inhibits the mineralization of osteoblastic MC3T3-E1 cells through glucose-induced increase in the receptor for AGEs. Hormone and Metabolic Research 2007. 39 871-875. (https://doi.org/10.1055/s-2007-991157)
42. Valcourt U, Merle B, Gineyts E, Viguet-Carrin S, Delmas PD, Garnero P. Non-enzymatic glycation of bone collagen modifies osteoclastic activity and differentiation. Journal of Biological Chemistry 2007. 282 5691-5703. (https://doi.org/10.1074/jbc.M610536200)
43. Notsu M, Kanazawa I, Takeno A, Yokomoto-Umakoshi M, Tanaka KI, Yamaguchi T, Sugimoto T. Advanced glycation end product 3 (AGE3) increases apoptosis and the expression of sclerostin by stimulating TGF-β expression and secretion in osteocyte-like MLO-Y4-A2 cells. Calcified Tissue International 2017. 100 402-411. (https://doi.org/10.1007/s00223-017-0243-x)
44. Tanaka K, Yamaguchi T, Kanazawa I, Sugimoto T. Effects of high glucose and advanced glycation end products on the expressions of sclerostin and RANKL as well as apoptosis in osteocyte-like MLO-Y4-A2 cells. Biochemical and Biophysical Research Communications 2015. 461 193-199. (https://doi.org/10.1016/j.bbrc.2015.02.091)
45. Acevedo C, Sylvia M, Schaible E, Graham JL, Stanhope KL, Metz LN, Gludovatz B, Schwartz AV, Ritchie RO, Alliston TN, et al Contributions of material properties and structure to increased bone fragility for a given bone mass in the UCD-T2DM rat model of type 2 diabetes. Journal of Bone and Mineral Research 2018. 33 1066-1075. (https://doi.org/10.1002/jbmr.3393)
46. Verroken C, Zmierczak HG, Goemaere S, Kaufman JM, Lapauw B. Insulin resistance is associated with smaller cortical bone size in nondiabetic men at the age of peak bone mass. Journal of Clinical Endocrinology and Metabolism 2017. 102 1807-1815. (https://doi.org/10.1210/jc.2016-3609)
47. Nilsson AG, Sundh D, Johansson L, Nilsson M, Mellström D, Rudäng R, Zoulakis M, Wallander M, Darelid A, Lorentzon M. Type 2 diabetes mellitus is associated with better bone microarchitecture but lower bone material strength and poorer physical function in elderly women: a population-based study. Journal of Bone and Mineral Research 2017. 32 1062-1071. (https://doi.org/10.1002/jbmr.3057)
48. Saito M, Fujii K, Mori Y, Marumo K. Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporosis International 2006. 17 1514-1523. (https://doi.org/10.1007/s00198-006-0155-5)
49. Campbell GM, Tiwari S, Picke AK, Hofbauer C, Rauner M, Morlock MM, Hofbauer LC, Glüer CC. Effects of insulin therapy on porosity, non-enzymatic glycation and mechanical competence in the bone of rats with type 2 diabetes mellitus. Bone 2016. 91 186-193. (https://doi.org/10.1016/j.bone.2016.08.003)
50. Creecy A, Uppuganti S, Unal M, Clay Bunn R, Voziyan P, Nyman JS. Low bone toughness in the TallyHO model of juvenile type 2 diabetes does not worsen with age. Bone 2018. 110 204-214. (https://doi.org/10.1016/j.bone.2018.02.005)
51. Hunt HB, Pearl JC, Diaz DR, King KB, Donnelly E. Bone tissue collagen maturity and mineral content increase with sustained hyperglycemia in the KK-Ay murine model of type 2 diabetes. Journal of Bone and Mineral Research 2018. 33 921-929. (https://doi.org/10.1002/jbmr.3365)
52. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H. Advanced glycosylation end products in patients with diabetic nephropathy. New England Journal of Medicine 1991. 325 836-842. (https://doi.org/10.1056/NEJM199109193251202)
53. Schwartz AV, Garnero P, Hillier TA, Sellmeyer DE, Strotmeyer ES, Feingold KR, Resnick HE, Tylavsky FA, Black DM, Cummings SR, et al Pentosidine and increased fracture risk in older adults with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2009. 94 2380-2386. (https://doi.org/10.1210/jc.2008-2498)
54. Phimphilai M, Pothacharoen P, Kongtawelert P, Chattipakorn N. Impaired osteogenic differentiation and enhanced cellular receptor of advanced glycation end products sensitivity in patients with type 2 diabetes. Journal of Bone and Mineral Metabolism 2017. 35 631-641. (https://doi.org/10.1007/s00774-016-0800-9)
55. Choi YJ, Ock SY, Jin Y, Lee JS, Kim SH, Chung YS. Urinary pentosidine levels negatively associates with trabecular bone scores in patients with type 2 diabetes mellitus. Osteoporosis International 2018. 29 907-915. (https://doi.org/10.1007/s00198-017-4359-7)
56. Stolk RP, Van Daele PL, Pols HA, Burger H, Hofman A, Birkenhäger JC, Lamberts SW, Grobbee DE. Hyperinsulinemia and bone mineral density in an elderly population: the Rotterdam study. Bone 1996. 18 545-549. (https://doi.org/10.1016/8756-3282(96)00079-8)
57. Wei J, Shimazu J, Makinistoglu MP, Maurizi A, Kajimura D, Zong H, Takarada T, Lezaki T, Pessin JE, Hinoi E, et al Glucose uptake and runx2 synergize to orchestrate osteoblast differentiation and bone formation. Cell 2015. 161 1576-1591. (https://doi.org/10.1016/j.cell.2015.05.029)
58. Napoli N, Strollo R, Paladini A, Briganti SI, Pozzilli P, Epstein S. The alliance of mesenchymal stem cells, bone, and diabetes. International Journal of Endocrinology 2014. 2014 690783 (https://doi.org/10.1155/2014/690783)
59. Klein GL. Insulin and bone: recent developments. World Journal of Diabetes 2014. 5 14-16. (https://doi.org/10.4239/wjd.v5.i1.14)
60. Starup-Linde J, Vestergaard P. Biochemical bone turnover markers in diabetes mellitus - a systematic review. Bone 2016. 82 69-78. (https://doi.org/10.1016/j.bone.2015.02.019)
61. Jiffri EH. Impact of non-insulin dependent diabetes mellitus on bone structure biomarkers in postmenopausal obese women. Advances in Obesity, Weight Management and Control 2017. 7 218-222. (https://doi.org/10.15406/aowmc.2017.07.00184)
62. Maghbooli Z, Shabani P, Gorgani-Firuzjaee S, Hossein-Nezhad A. The association between bone turnover markers and microvascular complications of type 2 diabetes. Journal of Diabetes and Metabolic Disorders 2016. 15 51 (https://doi.org/10.1186/s40200-016-0274-2)
63. Kulkarni SV, Meenatchi S, Reeta R, Ramesh R, Srinivasan AR, Lenin C. Association of glycemic status with bone turnover markers in type 2 diabetes mellitus. International Journal of Applied and Basic Medical Research 7 247-251. (https://doi.org/10.4103/ijabmr.IJABMR_35_17)
64. Capoglu I, Ozkan A, Ozkan B, Umudum Z. Bone turnover markers in patients with type 2 diabetes and their correlation with glycosylated haemoglobin levels. Journal of International Medical Research 36 1392-1398. (https://doi.org/10.1177/147323000803600629)
65. Miranda C, Giner M, Montoya MJ, Vázquez MA, Miranda MJ, Pérez-Cano R. Influence of high glucose and advanced glycation end-products (ages) levels in human osteoblast-like cells gene expression. BMC Musculoskeletal Disorders 2016. 17 377 (https://doi.org/10.1186/s12891-016-1228-z)
66. Ehnert S, Freude T, Ihle C, Mayer L, Braun B, Graeser J, Flesch I, Stöckle U, Nussler AK, Pscherer S. Factors circulating in the blood of type 2 diabetes mellitus patients affect osteoblast maturation - description of a novel in vitro model. Experimental Cell Research 2015. 332 247-258. (https://doi.org/10.1016/j.yexcr.2014.12.011)
67. Kume S, Kato S, Yamagishi S, Inagaki Y, Ueda S, Arima N, Okawa T, Kojiro M, Nagata K. Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. Journal of Bone and Mineral Research 2005. 20 1647-1658. (https://doi.org/10.1359/JBMR.050514)
68. Alikhani M, Alikhani Z, Boyd C, MacLellan CM, Raptis M, Liu R, Pischon N, Trackman PC, Gerstenfeld L, Graves DT. Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone 2007. 40 345-353. (https://doi.org/10.1016/j.bone.2006.09.011)
69. López-Herradón A, Portal-Núñez S, García-Martín A, Lozano D, Pérez-Martínez FC, Ceña V, Esbrit P. Inhibition of the canonical Wnt pathway by high glucose can be reversed by parathyroid hormone-related protein in osteoblastic cells. Journal of Cellular Biochemistry 2013. 114 1908-1916. (https://doi.org/10.1002/jcb.24535)
70. Picke AK, Salbach-Hirsch J, Hintze V, Rother S, Rauner M, Kascholke C, Möller S, Bernhardt R, Rammelt S, Pisabarro MT, et al Sulfated hyaluronan improves bone regeneration of diabetic rats by binding sclerostin and enhancing osteoblast function. Biomaterials 2016. 96 11-23. (https://doi.org/10.1016/j.biomaterials.2016.04.013)
71. Picke AK, Rauner M, Hofbauer LC, Hamann C. Eine hyperglykämie hemmt die osteoblastenfunktionen in vitro. Osteologie 2014. 23 79-85. (https://doi.org/10.1055/s-0037-1620044)
72. Kim TY, Schafer AL. Diabetes and bone marrow adiposity. Current Osteoporosis Reports 2016. 14 337-344. (https://doi.org/10.1007/s11914-016-0336-x)
73. Grey A, Beckley V, Doyle A, Fenwick S, Horne A, Gamble G, Bolland M. Pioglitazone increases bone marrow fat in type 2 diabetes: results from a randomized controlled trial. European Journal of Endocrinology 2012. 166 1087-1091. (https://doi.org/10.1530/EJE-11-1075)
74. Sheu Y, Amati F, Schwartz AV, Danielson ME, Li X, Boudreau R, Cauley JA. & Osteoporotic Fractures in Men (MrOS) Research Group. Vertebral bone marrow fat, bone mineral density and diabetes: the osteoporotic fractures in men (MrOS) study. Bone 2017. 97 299-305. (https://doi.org/10.1016/j.bone.2017.02.001)
75. Hjortdahl P, Halstensen A, Høiby EA, Andrew M, Brandtzaeg P, Gaustad P. The challenges of differential diagnosis of infections caused by beta-hemolytic streptococci. Tidsskrift for den Norske Laegeforening 1990. 110 2634-2637.
76. Hamann C, Goettsch C, Mettelsiefen J, Henkenjohann V, Rauner M, Hempel U, Bernhardt R, Fratzl-Zelman N, Roschger P, Rammelt S, et al Delayed bone regeneration and low bone mass in a rat model of insulin-resistant type 2 diabetes mellitus is due to impaired osteoblast function. American Journal of Physiology: Endocrinology and Metabolism 2011. 301 E1220-8. (https://doi.org/10.1152/ajpendo.00378.2011)
77. Lattanzio S, Santilli F, Liani R, Vazzana N, Ueland T, Di Fulvio P, Formoso G, Consoli A, Aukrust P, Davì G. Circulating dickkopf-1 in diabetes mellitus: association with platelet activation and effects of improved metabolic control and low-dose aspirin. Journal of the American Heart Association 2014. 3 e001000 (https://doi.org/10.1161/JAHA.114.001000)
78. Braga Gomes K, Fontana Rodrigues K, Fernandes AP. The role of transforming growth factor-beta in diabetic nephropathy. International Journal of Medical Genetics 2014. 2014 1-6. (https://doi.org/10.1155/2014/180270)
79. Kim S, Koga T, Isobe M, Kern BE, Yokochi T, Chin YE, Karsenty G, Taniguchi T, Takayanagi H. Stat1 functions as a cytoplasmic attenuator of Runx2 in the transcriptional program of osteoblast differentiation. Genes and Development 2003. 17 1979-1991. (https://doi.org/10.1101/gad.1119303)
80. Khan MP, Singh AK, Joharapurkar AA, Yadav M, Shree S, Kumar H, Gurjar A, Mishra JS, Tiwari MC, Nagar GK, et al Pathophysiological mechanism of bone loss in type 2 diabetes involves inverse regulation of osteoblast function by PGC-1α and Skeletal muscle atrogenes: AdipoR1 as a potential target for reversing diabetes-induced osteopenia. Diabetes 2015. 64 2609-2623. (https://doi.org/10.2337/db14-1611)
81. Hardouin P, Rharass T, Lucas S. Bone marrow adipose tissue: to be or not to be a typical adipose tissue? Frontiers in Endocrinology 2016. 7 85 (https://doi.org/10.3389/fendo.2016.00085)
82. Dallas SL, Prideaux M, Bonewald LF. The osteocyte: an endocrine cell& and more. Endocrine Reviews 2013. 34 658-690. (https://doi.org/10.1210/er.2012-1026)
83. Mabilleau G, Perrot R, Flatt PR, Irwin N, Chappard D. High fat-fed diabetic mice present with profound alterations of the osteocyte network. Bone 2016. 90 99-106. (https://doi.org/10.1016/j.bone.2016.06.008)
84. Villarino ME, Sánchez LM, Bozal CB, Ubios AM. Influence of short-term diabetes on osteocytic lacunae of alveolar bone. A histomorphometric study. Acta Odontologica Latinoamericana 2006. 19 23-28.
85. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, et al Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO Journal 2003. 22 6267-6276. (https://doi.org/10.1093/emboj/cdg599)
86. Xiong J, O’Brien CA. Osteocyte RANKL: new insights into the control of bone remodeling. Journal of Bone and Mineral Research 2012. 27 499-505. (https://doi.org/10.1002/jbmr.1547)
87. Catalfamo DL, Britten TM, Storch DL, Calderon NL, Sorenson HL, Wallet SM. Hyperglycemia induced and intrinsic alterations in type 2 diabetes-derived osteoclast function. Oral Diseases 2013. 19 303-312. (https://doi.org/10.1111/odi.12002)
88. García-Martín A, Rozas-Moreno P, Reyes-García R, Morales-Santana S, García-Fontana B, García-Salcedo JA, Muñoz-Torres M. Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 2012. 97 234-241. (https://doi.org/10.1210/jc.2011-2186)
89. Silswal N, Touchberry CD, Daniel DR, McCarthy DL, Zhang S, Andresen J, Stubbs JR, Wacker MJ. FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability. American Journal of Physiology: Endocrinology and Metabolism 2014. 307 E426-E436. (https://doi.org/10.1152/ajpendo.00264.2014)
90. Ärnlöv J, Carlsson AC, Sundström J, Ingelsson E, Larsson A, Lind L, Larsson TE. Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology. Clinical Journal of the American Society of Nephrology 2013. 8 781-786. (https://doi.org/10.2215/CJN.09570912)
91. Hu X, Ma X, Luo Y, Xu Y, Xiong Q, Pan X, Bao Y, Jia W. Elevation in fibroblast growth factor 23 and its value for identifying subclinical atherosclerosis in first-degree relatives of patients with diabetes. Scientific Reports 2016. 6 34696 (https://doi.org/10.1038/srep34696)
92. Tamasi JA, Arey BJ, Bertolini DR, Feyen JHM. Characterization of bone structure in leptin receptor-deficient Zucker (fa/fa) rats. Journal of Bone and Mineral Research 2003. 18 1605-1611. (https://doi.org/10.1359/jbmr.2003.18.9.1605)
93. Xu F, Ye YP, Dong YH, Guo FJ, Chen AM, Huang SL. Inhibitory effects of high glucose/insulin environment on osteoclast formation and resorption in vitro. Journal of Huazhong University of Science and Technology 2013. 33 244-249. (https://doi.org/10.1007/s11596-013-1105-z)
94. Cunha JS, Ferreira VM, Maquigussa E, Naves MA, Boim MA. Effects of high glucose and high insulin concentrations on osteoblast function in vitro. Cell and Tissue Research 2014. 358 249-256. (https://doi.org/10.1007/s00441-014-1913-x)
95. Xu J, Yue F, Wang J, Chen L, Qi W. High glucose inhibits receptor activator of nuclear factor-κB ligand-induced osteoclast differentiation via downregulation of v-ATPase V0 subunit d2 and dendritic cell-specific transmembrane protein. Molecular Medicine Reports 2015. 11 865-870. (https://doi.org/10.3892/mmr.2014.2807)
96. Chen YL, Qiao YC, Xu Y, Ling W, Pan YH, Huang YC, Geng LJ, Zhao HL, Zhang XX. Serum TNF-α concentrations in type 2 diabetes mellitus patients and diabetic nephropathy patients: a systematic review and meta-analysis. Immunology Letters 2017. 186 52-58. (https://doi.org/10.1016/j.imlet.2017.04.003)
97. Goto H, Hozumi A, Osaki M, Fukushima T, Sakamoto K, Yonekura A, Tomita M, Furukawa K, Shindo H, Baba H. Primary human bone marrow adipocytes support TNF-α-induced osteoclast differentiation and function through RANKL expression. Cytokine 2011. 56 662-668. (https://doi.org/10.1016/j.cyto.2011.09.005)
98. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, et al Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. Journal of Experimental Medicine 2000. 191 275-286. (https://doi.org/10.1084/jem.191.2.275)
99. Fuller K, Murphy C, Kirstein B, Fox SW, Chambers TJ. TNFalpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. Endocrinology 2002. 143 1108-1118. (https://doi.org/10.1210/endo.143.3.8701)
100. Oh SR, Sul OJ, Kim YY, Kim HJ, Yu R, Suh JH, Choi HS. Saturated fatty acids enhance osteoclast survival. Journal of Lipid Research 2010. 51 892-899. (https://doi.org/10.1194/jlr.M800626)
101. Cornish J, MacGibbon A, Lin JM, Watson M, Callon KE, Tong PC, Dunford JE, van der Does Y, Williams GA, Grey AB, et al Modulation of osteoclastogenesis by fatty acids. Endocrinology 2008. 149 5688-5695. (https://doi.org/10.1210/en.2008-0111)
102. Scheller EL, Cawthorn WP, Burr AA, Horowitz MC, MacDougald OA. Marrow adipose tissue: trimming the fat. Trends in Endocrinology and Metabolism 2016. 27 392-403. (https://doi.org/10.1016/j.tem.2016.03.016)
103. Baum T, Yap SP, Karampinos DC, Nardo L, Kuo D, Burghardt AJ, Masharani UB, Schwartz AV, Li X, Link TM. Does vertebral bone marrow fat content correlate with abdominal adipose tissue, lumbar spine bone mineral density, and blood biomarkers in women with type 2 diabetes mellitus? Journal of Magnetic Resonance Imaging 2012. 35 117-124. (https://doi.org/10.1002/jmri.22757)
104. de Araújo IM, Salmon CEG, Nahas AK, Nogueira-Barbosa MH, Elias J, de Paula FJA. Marrow adipose tissue spectrum in obesity and type 2 diabetes mellitus. European Journal of Endocrinology 2017. 176 21-30. (https://doi.org/10.1530/EJE-16-0448)
105. Patsch JM, Li X, Baum T, Yap SP, Karampinos DC, Schwartz AV, Link TM. Bone marrow fat composition as a novel imaging biomarker in postmenopausal women with prevalent fragility fractures. Journal of Bone and Mineral Research 2013. 28 1721-1728. (https://doi.org/10.1002/jbmr.1950)
106. Kurtz TW, Morris RC, Pershadsingh HA. The Zucker fatty rat as a genetic model of obesity and hypertension. Hypertension 1989. 13 896-901. (https://doi.org/10.1161/01.HYP.13.6.896)
107. Picke AK, Gordaliza Alaguero I, Campbell GM, Glüer CC, Salbach-Hirsch J, Rauner M, Hofbauer LC, Hofbauer C. Bone defect regeneration and cortical bone parameters of type 2 diabetic rats are improved by insulin therapy. Bone 2016. 82 108-115. (https://doi.org/10.1016/j.bone.2015.06.001)
108. Picke AK, Sylow L, Møller LL V, Kjøbsted R, Schmidt FN, Steejn MW, Salbach-Hirsch J, Hofbauer C, Blüher M, Saalbach A, et al Differential effects of high-fat diet and exercise training on bone and energy metabolism. Bone 2018. 116 120-134. (https://doi.org/10.1016/j.bone.2018.07.015)
109. Keats EC, Dominguez JM, Grant MB, Khan ZA. Switch from canonical to noncanonical Wnt signaling mediates high glucose-induced adipogenesis. Stem Cells 2014. 32 1649-1660. (https://doi.org/10.1002/stem.1659)
110. Okamoto M, Udagawa N, Uehara S, Maeda K, Yamashita T, Nakamichi Y, Kato H, Saito N, Minami Y, Takahashi N, et al Noncanonical Wnt5a enhances Wnt/β-catenin signaling during osteoblastogenesis. Scientific Reports 2014. 4 4493 (https://doi.org/10.1038/srep04493)
111. Cawthorn WP, Bree AJ, Yao Y, Du B, Hemati N, Martinez-Santibañez G, MacDougald OA. Wnt6, Wnt10a and Wnt10b inhibit adipogenesis and stimulate osteoblastogenesis through a β-catenin-dependent mechanism. Bone 2012. 50 477-489. (https://doi.org/10.1016/j.bone.2011.08.010)
112. Ross SE, Hemati N, Longo KA, Bennett CN, Lucas PC, Erickson RL, MacDougald OA. Inhibition of adipogenesis by Wnt signaling. Science 2000. 289 950-953. (https://doi.org/10.1126/science.289.5481.950)
113. Song L, Liu M, Ono N, Bringhurst FR, Kronenberg HM, Guo J. Loss of wnt/β-catenin signaling causes cell fate shift of preosteoblasts from osteoblasts to adipocytes. Journal of Bone and Mineral Research 2012. 27 2344-2358. (https://doi.org/10.1002/jbmr.1694)
114. Zhou J, Wang S, Qi Q, Yang X, Zhu E, Yuan H, Li X, Liu Y, Li X, Wang B. Nuclear factor I-C reciprocally regulates adipocyte and osteoblast differentiation via control of canonical Wnt signaling. FASEB Journal 2017. 31 1939-1952. (https://doi.org/10.1096/fj.201600975RR)
115. Picke AK, Campbell GM, Blüher M, Krügel U, Schmidt FN, Tsourdi E, Winzer M, Rauner M, Vukicevic V, Busse B, et al Thy-1 (CD90) promotes bone formation and protects against obesity. Science Translational Medicine 2018. 10 eaao6806 (https://doi.org/10.1126/scitranslmed.aao6806)
116. Piccinin MA, Khan ZA. Pathophysiological role of enhanced bone marrow adipogenesis in diabetic complications. Adipocyte 3 263-272. (https://doi.org/10.4161/adip.32215)
117. Sarkar PD, Choudhury AB. Relationships between serum osteocalcin levels versus blood glucose, insulin resistance and markers of systemic inflammation in central Indian type 2 diabetic patients. European Review for Medical and Pharmacological Sciences 2013. 17 1631-1635.
118. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. Journal of Clinical Investigation 2005. 115 1111-1119. (https://doi.org/10.1172/JCI25102)
119. Aguirre L, Napoli N, Waters D, Qualls C, Villareal DT, Armamento-Villareal R. Increasing adiposity is associated with higher adipokine levels and lower bone mineral density in obese older adults. Journal of Clinical Endocrinology and Metabolism 2014. 99 3290-3297. (https://doi.org/10.1210/jc.2013-3200)
120. Frommer K, Schäffler A, Lange U, Rehart S, Steinmeyer J, Rickert M, Müller-Ladner U, Neumann E. 02.03 Influence of free fatty acids on osteoblasts and osteoclasts in rheumatic diseases. New Players and Novel Targets in Inflammation 2017. A9.1-A9. (https://doi.org/10.1136/annrheumdis-2016-211050.3)
121. Regazzetti C, Peraldi P, Grémeaux T, Najem-Lendom R, Ben-Sahra I, Cormont M, Bost F, Le Marchand-Brustel Y, Tanti JF, Giorgetti-Peraldi S. Hypoxia decreases insulin signaling pathways in adipocytes. Diabetes 2009. 58 95-103. (https://doi.org/10.2337/db08-0457)
122. Hosogai N, Fukuhara A, Oshima K, Miyata Y, Tanaka S, Segawa K, Furukawa S, Tochino Y, Komuro R, Matsuda M, et al Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 2007. 56 901-911. (https://doi.org/10.2337/db06-0911)
123. Wang B, Wood IS, Trayhurn P. Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes. Pflugers Archiv 2007. 455 479-492. (https://doi.org/10.1007/s00424-007-0301-8)
124. Kraakman MJ, Murphy AJ, Jandeleit-Dahm K, Kammoun HL. Macrophage polarization in obesity and type 2 diabetes: weighing down our understanding of macrophage function? Frontiers in Immunology 2014. 5 470 (https://doi.org/10.3389/fimmu.2014.00470)
125. Kusumbe AP, Ramasamy SK, Adams RH. Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone. Nature 2014. 507 323-328. (https://doi.org/10.1038/nature13145)
126. Oikawa A, Siragusa M, Quaini F, Mangialardi G, Katare RG, Caporali A, van Buul JD, van Alphen FPJ, Graiani G, Spinetti G, et al Diabetes mellitus induces bone marrow microangiopathy. Arteriosclerosis, Thrombosis, and Vascular Biology 2010. 30 498-508. (https://doi.org/10.1161/ATVBAHA.109.200154)
127. Fadini GP. An underlying principle for the study of circulating progenitor cells in diabetes and its complications. Diabetologia 2008. 51 1091-1094. (https://doi.org/10.1007/s00125-008-1021-0)
128. Mangialardi G, Katare R, Oikawa A, Meloni M, Reni C, Emanueli C, Madeddu P. Diabetes causes bone marrow endothelial barrier dysfunction by activation of the RhoA-Rho-associated kinase signaling pathway. Arteriosclerosis, Thrombosis, and Vascular Biology 2013. 33 555-564. (https://doi.org/10.1161/ATVBAHA.112.300424)
129. Ferraro F, Lymperi S, Méndez-Ferrer S, Saez B, Spencer JA, Yeap BY, Masselli E, Graiani G, Prezioso L, Rizzini EL, et al Diabetes impairs hematopoietic stem cell mobilization by altering niche function. Science Translational Medicine 2011. 3 104ra101 (https://doi.org/10.1126/scitranslmed.3002191)
130. Egan CG, Lavery R, Caporali F, Fondelli C, Laghi-Pasini F, Dotta F, Sorrentino V. Generalised reduction of putative endothelial progenitors and CXCR4-positive peripheral blood cells in type 2 diabetes. Diabetologia 2008. 51 1296-1305. (https://doi.org/10.1007/s00125-008-0939-6)
131. Fadini GP, Miorin M, Facco M, Bonamico S, Baesso I, Grego F, Menegolo M, de Kreutzenberg SV, Tiengo A, Agostini C, et al Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. Journal of the American College of Cardiology 2005. 45 1449-1457. (https://doi.org/10.1016/j.jacc.2004.11.067)
132. Spinetti G, Cordella D, Fortunato O, Sangalli E, Losa S, Gotti A, Carnelli F, Rosa F, Riboldi S, Sessa F, et al Global remodeling of the vascular stem cell niche in bone marrow of diabetic patients: implication of the microRNA-155/FOXO3a signaling pathway. Circulation Research 2013. 112 510-522. (https://doi.org/10.1161/CIRCRESAHA.112.300598)
133. Thum T, Fraccarollo D, Schultheiss M, Froese S, Galuppo P, Widder JD, Tsikas D, Ertl G, Bauersachs J. Endothelial nitric oxide synthase uncoupling impairs endothelial progenitor cell mobilization and function in diabetes. Diabetes 2007. 56 666-674. (https://doi.org/10.2337/db06-0699)
134. Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, Levine JP, Gurtner GC. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 2002. 106 2781-2786. (https://doi.org/10.1161/01.CIR.0000039526.42991.93)
135. Cao C, Zhang H, Gong L, He Y, Zhang N. High glucose conditions suppress the function of bone marrow-derived endothelial progenitor cells via inhibition of the eNOS-caveolin-1 complex. Molecular Medicine Reports 2012. 5 341-346. (https://doi.org/10.3892/mmr.2011.644)
136. Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K, Zeiher AM, Dimmeler S. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nature Medicine 2003. 9 1370-1376. (https://doi.org/10.1038/nm948)
137. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circulation Research 2005. 96 939-949. (https://doi.org/10.1161/01.RES.0000163635.62927.34)
138. Capla JM, Grogan RH, Callaghan MJ, Galiano RD, Tepper OM, Ceradini DJ, Gurtner GC. Diabetes impairs endothelial progenitor cell-mediated blood vessel formation in response to hypoxia. Plastic and Reconstructive Surgery 2007. 119 59-70. (https://doi.org/10.1097/01.prs.0000244830.16906.3f)
139. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clinical Science 2012. 122 253-270. (https://doi.org/10.1042/CS20110386)
140. Gilbert MP, Pratley RE. The impact of diabetes and diabetes medications on bone health. Endocrine Reviews 2015. 36 194-213. (https://doi.org/10.1210/er.2012-1042)
141. Palermo A, D’Onofrio L, Buzzetti R, Manfrini S, Napoli N. Pathophysiology of bone fragility in patients with diabetes. Calcified Tissue International 2017. 100 122-132. (https://doi.org/10.1007/s00223-016-0226-3)
142. Napoli N, Schwartz AV, Schafer AL, Vittinghoff E, Cawthon PM, Parimi N, Orwoll E, Strotmeyer ES, Hoffman AR, Barrett-Connor E, et al Vertebral fracture risk in diabetic elderly men: the MrOS study. Journal of Bone and Mineral Research 2018. 33 63-69. (https://doi.org/10.1002/jbmr.3287)
143. Stage TB, Christensen MMH, Jørgensen NR, Beck-Nielsen H, Brøsen K, Gram J, Frost M. Effects of metformin, rosiglitazone and insulin on bone metabolism in patients with type 2 diabetes. Bone 2018. 112 35-41. (https://doi.org/10.1016/j.bone.2018.04.004)
144. Beck GR, Khazai NB, Bouloux GF, Camalier CE, Lin Y, Garneys LM, Siqueira J, Peng L, Pasquel F, et al The effects of thiazolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes. Translational Research 2013. 161 145-155. (https://doi.org/10.1016/j.trsl.2012.08.006)
145. Losada-Grande E, Hawley S, Soldevila B, Martínez-Laguna D, Nogués X, Díez-Pérez A, Puig-Domingo M, Mauricio D, Prieto-Alhambra D. Insulin use and excess fracture risk in patients with type 2 diabetes: a propensity-matched cohort analysis. Scientific Reports 2017. 7 3781 (https://doi.org/10.1038/s41598-017-03748-z)
146. Losada E, Soldevila B, Ali MS, Martínez-Laguna D, Nogués X, Puig-Domingo M, Díez-Pérez A, Mauricio D, Prieto-Alhambra D. Real-world antidiabetic drug use and fracture risk in 12,277 patients with type 2 diabetes mellitus: a nested case-control study. Osteoporosis International 2018. 29 2079-2086. (https://doi.org/10.1007/s00198-018-4581-y)
147. Schopman JE, Simon ACR, Hoefnagel SJM, Hoekstra JBL, Scholten RJPM, Holleman F. The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis. Diabetes/Metabolism Research and Reviews 2014. 30 11-22. (https://doi.org/10.1002/dmrr.2470)
148. Starup-Linde J, Gregersen S, Frost M, Vestergaard P. Use of glucose-lowering drugs and risk of fracture in patients with type 2 diabetes. Bone 2017. 95 136-142. (https://doi.org/10.1016/j.bone.2016.11.026)
149. Yamada C, Yamada Y, Tsukiyama K, Yamada K, Udagawa N, Takahashi N, Tanaka K, Drucker DJ, Seino Y, Inagaki N. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology 2008. 149 574-579. (https://doi.org/10.1210/en.2007-1292)
150. Ma X, Meng J, Jia M, Bi L, Zhou Y, Wang Y, Hu J, He G, Luo X. Exendin-4, a glucagon-like peptide-1 receptor agonist, prevents osteopenia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats. Journal of Bone and Mineral Research 2013. 28 1641-1652. (https://doi.org/10.1002/jbmr.1898)
151. Lu N, Sun H, Yu J, Wang X, Liu D, Zhao L, Sun L, Zhao H, Tao B, Liu J. Glucagon-like peptide-1 receptor agonist Liraglutide has anabolic bone effects in ovariectomized rats without diabetes. PLoS ONE 2015. 10 e0132744 (https://doi.org/10.1371/journal.pone.0132744)
152. Pereira M, Jeyabalan J, Jørgensen CS, Hopkinson M, Al-Jazzar A, Roux JP, Chavassieux P, Orriss IR, Cleasby ME, Chenu C. Chronic administration of glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice. Bone 2015. 81 459-467. (https://doi.org/10.1016/j.bone.2015.08.006)
153. Li J, Fu LZ, Liu L, Xie F, Dai RC. Glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide alters bone marrow exosome-mediated miRNA signal pathways in ovariectomized rats with type 2 diabetes. Medical Science Monitor 2017. 23 5410-5419. (https://doi.org/10.12659/MSM.906603)
154. Wen B, Zhao L, Zhao H, Wang X. Liraglutide exerts a bone-protective effect in ovariectomized rats with streptozotocin-induced diabetes by inhibiting osteoclastogenesis. Experimental and Therapeutic Medicine 2018. 15 5077-5083. (https://doi.org/10.3892/etm.2018.6043)
155. Nuche-Berenguer B, Moreno P, Portal-Núñez S, Dapía S, Esbrit P, Villanueva-Peñacarrillo ML. Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states. Regulatory Peptides 2010. 159 61-66. (https://doi.org/10.1016/j.regpep.2009.06.010)
156. Nuche-Berenguer B, Moreno P, Esbrit P, Dapía S, Caeiro JR, Cancelas J, Haro-Mora JJ, Villanueva-Peñacarrillo ML. Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states. Calcified Tissue International 2009. 84 453-461. (https://doi.org/10.1007/s00223-009-9220-3)
157. Kim JY, Lee SK, Jo KJ, Song DY, Lim DM, Park KY, Bonewald LF, Kim BJ. Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes. Life Sciences 2013. 92 533-540. (https://doi.org/10.1016/j.lfs.2013.01.001)
158. Monami M, Dicembrini I, Antenore A, Mannucci E. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care 2011. 34 2474-2476. (https://doi.org/10.2337/dc11-1099)
159. Mabilleau G, Mieczkowska A, Chappard D. Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials. Journal of Diabetes 2014. 6 260-266. (https://doi.org/10.1111/1753-0407.12102)
160. Su B, Sheng H, Zhang M, Bu L, Yang P, Li L, Li F, Sheng C, Han Y, Qu S, et al Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists’ treatment: a meta-analysis of randomized controlled trials. Endocrine 2015. 48 107-115. (https://doi.org/10.1007/s12020-014-0361-4)
161. Driessen JHM, de Vries F, van Onzenoort H, Harvey NC, Neef C, van Bergh JPW, den Vestergaard P, Henry RMA. The use of incretins and fractures - a meta-analysis on population-based real life data. British Journal of Clinical Pharmacology 2017. 83 923-926. (https://doi.org/10.1111/bcp.13167)
162. Iepsen EW, Lundgren JR, Hartmann B, Pedersen O, Hansen T, Jørgensen NR, Jensen JEB, Holst JJ, Madsbad S, Torekov SS. GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women. Journal of Clinical Endocrinology and Metabolism 2015. 100 2909-2917. (https://doi.org/10.1210/jc.2015-1176)
163. Mosenzon O, Wei C, Davidson J, Scirica BM, Yanuv I, Rozenberg A, Hirshberg B, Cahn A, Stahre C, Strojek K, et al Incidence of fractures in patients with type 2 diabetes in the SAVOR-TIMI 53 trial. Diabetes Care 2015. 38 2142-2150. (https://doi.org/10.2337/dc15-1068)
164. Katsuno K, Fujimori Y, Takemura Y, Hiratochi M, Itoh F, Komatsu Y, Fujikura H, Isaji M. Sergliflozin, a novel selective inhibitor of low-affinity sodium-glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. Journal of Pharmacology and Experimental Therapeutics 2007. 320 323-330. (https://doi.org/10.1124/jpet.106.110296)
165. Hummel CS, Lu C, Loo DDF, Hirayama BA, Voss AA, Wright EM. Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2. American Journal of Physiology: Cell Physiology 2011. 300 C14-C21. (https://doi.org/10.1152/ajpcell.00388.2010)
166. Thrailkill KM, Clay Bunn R, Nyman JS, Rettiganti MR, Cockrell GE, Wahl EC, Uppuganti S, Lumpkin CK, Fowlkes JL. SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice. Bone 2016. 82 101-107. (https://doi.org/10.1016/j.bone.2015.07.025)
167. Taylor SI, Blau JE, Rother KI. Possible adverse effects of SGLT2 inhibitors on bone. Lancet. Diabetes and Endocrinology 2015. 3 8-10. (https://doi.org/10.1016/S2213-8587(14)70227-X)
168. Bolinder J, Ljunggren Ö, Johansson L, Wilding J, Langkilde AM, Sjöström CD, Sugg J, Parikh S. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes, Obesity and Metabolism 2014. 16 159-169. (https://doi.org/10.1111/dom.12189)
169. Ljunggren Ö, Bolinder J, Johansson L, Wilding J, Langkilde AM, Sjöström CD, Sugg J, Parikh S. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes, Obesity and Metabolism 2012. 14 990-999. (https://doi.org/10.1111/j.1463-1326.2012.01630.x)
170. Kohler S, Kaspers S, Salsali A, Zeller C, Woerle HJ. Analysis of fractures in patients with type 2 diabetes treated with empagliflozin in pooled data from placebo-controlled trials and a head-to-head study versus glimepiride. Diabetes Care 2018. 41 1809-1816. (https://doi.org/10.2337/dc17-1525)
171. Watts NB, Bilezikian JP, Usiskin K, Edwards R, Desai M, Law G, Meininger G. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 2016. 101 157-166. (https://doi.org/10.1210/jc.2015-3167)
172. Bilezikian JP, Watts NB, Usiskin K, Polidori D, Fung A, Sullivan D, Rosenthal N. Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin. Journal of Clinical Endocrinology and Metabolism 2016. 101 44-51. (https://doi.org/10.1210/jc.2015-1860)
173. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet 2011. 377 1276-1287. (https://doi.org/10.1016/S0140-6736(10)62349-5)
174. Dagdelen S, Sener D, Bayraktar M. Influence of type 2 diabetes mellitus on bone mineral density response to bisphosphonates in late postmenopausal osteoporosis. Advances in Therapy 24 1314-1320. (https://doi.org/10.1007/BF02877778)
175. Chandran M. Clinical aspects and management of osteoporosis and fragility fractures in patients with diabetes. Osteoporosis and Sarcopenia 2017. 3 123-127. (https://doi.org/10.1016/j.afos.2017.08.101)
176. Anagnostis P, Paschou SA, Gkekas NN, Artzouchaltzi AM, Christou K, Stogiannou D, Vryonidou A, Potoupnis M, Goulis DG. Efficacy of anti-osteoporotic medications in patients with type 1 and 2 diabetes mellitus: a systematic review. Endocrine 2018. 60 373-383. (https://doi.org/10.1007/s12020-018-1548-x)
177. Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, Chen C, Li L, Cattley RC, Van G, et al Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. Journal of Bone and Mineral Research 2009. 24 182-195. (https://doi.org/10.1359/jbmr.081112)
178. Napoli N, Pannacciulli N, Vittinghoff E, Crittenden D, Yun J, Wang A, Wagman R, Schwartz AV. Effect of denosumab on fasting glucose in women with diabetes or prediabetes from the FREEDOM trial. Diabetes/Metabolism Research and Reviews 2018. 34 e2991 (https://doi.org/10.1002/dmrr.2991)
179. Thomas T. Intermittent parathyroid hormone therapy to increase bone formation. Joint, Bone, Spine 2006. 73 262-269. (https://doi.org/10.1016/j.jbspin.2005.11.007)
180. Schwartz AV, Pavo I, Alam J, Disch DP, Schuster D, Harris JM, Krege JH. Teriparatide in patients with osteoporosis and type 2 diabetes. Bone 2016. 91 152-158. (https://doi.org/10.1016/j.bone.2016.06.017)
181. Langdahl BL, Silverman S, Fujiwara S, Saag K, Napoli N, Soen S, Enomoto H, Melby TE, Disch DP, Marin F, et al Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: integrated analysis of 4 prospective observational studies. Bone 2018. 116 58-66. (https://doi.org/10.1016/j.bone.2018.07.013)
182. Drake MT, Farr JN. Inhibitors of sclerostin: emerging concepts. Current Opinion in Rheumatology 2014. 26 447-452. (https://doi.org/10.1097/BOR.0000000000000073)
183. Sølling ASK, Harsløf T, Langdahl B. The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosis. Therapeutic Advances in Musculoskeletal Disease 2018. 10 105-115. (https://doi.org/10.1177/1759720X18775936)
184. Liu Y, Cao Y, Zhang S, Zhang W, Zhang B, Tang Q, Li Z, Wu J. Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials. Climacteric 2018. 21 189-195. (https://doi.org/10.1080/13697137.2018.1433655)